Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
242 participants
INTERVENTIONAL
2012-05-31
2022-09-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To Identify, compare and combine the predictive markers of AD,
* To better understand the pathophysiologic mechanisms of AD,
* To study the ability of different neuroimaging techniques to monitor AD's evolution.
For these purposes, detailed neuropsychological evaluations, biological measures and brain structural \& functional imaging measures are associated for a fully-comprehensive description of the different manifestations of AD through disease progression and toward identifying early markers.
Subjects are evaluated using neuropsychological tests of episodic memory (encoding vs. retrieval), executive functions (inhibition, flexibility, and updating processes), self-judgment, theory of mind, mental imagery and verbal fluency. A FDG-PET measure of resting state glucose consumption, an AV45-PET measure of amyloid deposition as well as anatomical, resting-state and activation fMRI scans are performed for each volonteer. In addition, blood and cerebro-spinal fluid samples will be performed to determine different biomarkers (Aβ1-40, Aβ1-42 and tPA as circulating blood proteins and Aβ40, Aβ42, tau and its phosphorylated form in CSF). The investigators also study the polymorphism of Apolipoprotein E as a genetic risk factor of AD.
One hundred and twenty healthy controls (40 young, 40 middle age and 40 elderly), 40 Mild Cognitive Impairment patients (MCI; i.e. isolated memory impairment and increased risk of developing AD) and 30 AD patients will be selected. Participants with increased risk of developing AD and without objective evidence will be also studied: 50 asymptomatic subjects from families carrying a genetic mutation with an autosomal dominant transmission (NORMA) and 40 Subjective Cognitive Impairment patients (SCI).
Clinical follow-up of patients will be completed during 36 months (18 months for AD patients), as a neuropsychological evaluation every 6 months. Comparable neuropsychological and imaging exams will be proposed once again after 18 months for all participants as well as after 36 months for elderly controls, NORMA and SCI \& MCI patients.
To study and compare the effectiveness of different in vivo markers (to predict cognitive decline in populations at risk of developing AD), each data set (i.e. modality) will be first analyzed independently from one another (intra-modality analyses), including inter-group comparisons, correlations and connectivity analyses, as well as longitudinal assessment of cognitive, biological and brain changes. Baseline data will also be analyzed in function of patient's clinical evolution to assess their predictive value. Comparisons and correlations between the different patterns of alterations will then be performed through inter-modality analyses. More specifically, the investigators will address the questions of the relationships between cognitive and cerebral alterations and structural / functional brain changes over our different patient samples, neuroimaging data sets, and through disease evolution.
This project is expected to identify specific and early markers of the MA and also to compare the diagnostic efficiency of different measures. It should contribute to better understand brain and cognitive alterations in AD. Finally, the investigators will be able to appreciate the dynamic properties of these alterations in the evolution of the disease through the longitudinal study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
FACTORIAL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Young controls
Memory assessment
Neuropsycological tests including clinical and original tests to compare differences between each populations.
Circulating biomarkers measure
ELISA tests from blood samples to compare differences between each populations.
ApoE4
Evaluation of apolipoprotein E polymorphism as a risk factor.
Brain imaging examination MRI and PET examinations
Structural and functional MRI FDG-PET to compare differences between each populations.
Middle age controls
Memory assessment
Neuropsycological tests including clinical and original tests to compare differences between each populations.
Circulating biomarkers measure
ELISA tests from blood samples to compare differences between each populations.
ApoE4
Evaluation of apolipoprotein E polymorphism as a risk factor.
Brain imaging examination MRI and PET examinations
Structural and functional MRI FDG-PET to compare differences between each populations.
Elderly controls
Memory assessment
Neuropsycological tests including clinical and original tests to compare differences between each populations.
Circulating biomarkers measure
ELISA tests from blood samples to compare differences between each populations.
ApoE4
Evaluation of apolipoprotein E polymorphism as a risk factor.
Brain imaging examination MRI and PET examinations
Structural and functional MRI FDG-PET to compare differences between each populations.
Asymptomatic subjects
Asymptomatic subjects from families carrying a genetic mutation with an autosomal dominant transmission
Memory assessment
Neuropsycological tests including clinical and original tests to compare differences between each populations.
Circulating biomarkers measure
ELISA tests from blood samples to compare differences between each populations.
ApoE4
Evaluation of apolipoprotein E polymorphism as a risk factor.
Brain imaging examination MRI and PET examinations
Structural and functional MRI FDG-PET to compare differences between each populations.
Subjectif Cognitive Impariment patients
Memory assessment
Neuropsycological tests including clinical and original tests to compare differences between each populations.
Circulating biomarkers measure
ELISA tests from blood samples to compare differences between each populations.
ApoE4
Evaluation of apolipoprotein E polymorphism as a risk factor.
Brain imaging examination MRI and PET examinations
Structural and functional MRI FDG-PET to compare differences between each populations.
Mild Cognitive Impairment patients
Memory assessment
Neuropsycological tests including clinical and original tests to compare differences between each populations.
Circulating biomarkers measure
ELISA tests from blood samples to compare differences between each populations.
ApoE4
Evaluation of apolipoprotein E polymorphism as a risk factor.
Brain imaging examination MRI and PET examinations
Structural and functional MRI FDG-PET to compare differences between each populations.
Alzheimer Disease patients
Memory assessment
Neuropsycological tests including clinical and original tests to compare differences between each populations.
Circulating biomarkers measure
ELISA tests from blood samples to compare differences between each populations.
ApoE4
Evaluation of apolipoprotein E polymorphism as a risk factor.
Brain imaging examination MRI and PET examinations
Structural and functional MRI FDG-PET to compare differences between each populations.
Non degenerative amnsesic syndrome
Memory assessment
Neuropsycological tests including clinical and original tests to compare differences between each populations.
Circulating biomarkers measure
ELISA tests from blood samples to compare differences between each populations.
ApoE4
Evaluation of apolipoprotein E polymorphism as a risk factor.
Brain imaging examination MRI and PET examinations
Structural and functional MRI FDG-PET to compare differences between each populations.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Memory assessment
Neuropsycological tests including clinical and original tests to compare differences between each populations.
Circulating biomarkers measure
ELISA tests from blood samples to compare differences between each populations.
ApoE4
Evaluation of apolipoprotein E polymorphism as a risk factor.
Brain imaging examination MRI and PET examinations
Structural and functional MRI FDG-PET to compare differences between each populations.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Native language: French
* Medical, neurological, neuropsychological and neuroradiological depth in accordance with the criteria for inclusion and exclusion-specific population, that is to say:
* Healthy young volunteers: between 18 and 40 years old; normal performances compared to the age and the educational level for all tests of the diagnostic battery (± 1.65 SD).
* Healthy Middle-aged volunteers: between 40 and 60 years old; without memory complaints, normal performances compared to the age and the educational level for all tests of the diagnostic battery (± 1.65 SD).
* Healthy Elderly volunteers: over 60 years old, living at home, without memory complaints, normal performances compared to the age and the educational level for all tests of the diagnostic battery (± 1.65 SD).
* SCI patients: over 60 years old ; memory complaints; memory complaint ; normal performances compared to the age and the educational level for all tests of the diagnostic battery (± 1.65 SD).
* MCI patients: presenting the current criteria for amnestic MCI including: i) memory complaint, ii) deficits of the episodic memory (lower performance of at least 1.65 SD from the norm for age and cultural level for one or more scores of episodic memory and iii) normal performances compared to the age and the educational level of all other cognitive functions as memory, including tests to assess cognitive abilities.
* Alzheimer's patients: presenting the standard criteria of NINCDS-ADRDA probable Alzheimer's disease, including abnormal global cognitive function and deficits in at least two cognitive domains identified by the diagnostic battery and a mild to moderate Alzheimer's disease (MMSE ≥ 15).
Exclusion Criteria
* A chronic neurological, psychiatric, endocrine, hepatic or infectious complaint
* A history of major disease (an uncontrolled diabetes, a lung, heart, metabolic, hematologic, endocrine disease or a severe cancer)
* A medication that may interfere with memory or metabolic measures
* A alcohol or drugs abuse
* The cons-indications to MRI (claustrophobia, metallic object in the body)
* A predominantly left-hand (score below 50% in Edinburgh Inventory)
* Protected adults, and persons not affiliated with a social security system will not participate in this study
* The inclusion of a participant in another biomedical research protocol
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
University Hospital, Caen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vincent de La Sayette, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Caen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GIP Cyceron
Caen, Calvados, France
Inserm - EPHE - University of Caen U1077
Caen, , France
University Hospital Côte de Nacre
Caen, , France
University Hospital Roger Salengro
Lille, , France
University Hospital Pontchaillou
Rennes, , France
University Hospital Rouen
Rouen, , France
University Hospital Tours
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kuhn E, Perrotin A, La Joie R, Touron E, Dautricourt S, Vanhoutte M, Vivien D, de La Sayette V, Chetelat G; Alzheimer's Disease Neuroimaging Initiative. Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum. Neurology. 2023 Jun 13;100(24):e2454-e2465. doi: 10.1212/WNL.0000000000207338. Epub 2023 Apr 21.
Kuhn E, Moulinet I, Perrotin A, La Joie R, Landeau B, Tomadesso C, Bejanin A, Sherif S, De La Sayette V, Desgranges B, Vivien D, Poisnel G, Chetelat G. Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time. Alzheimers Res Ther. 2019 Jul 8;11(1):61. doi: 10.1186/s13195-019-0514-z.
Gonneaud J, Arenaza-Urquijo EM, Fouquet M, Perrotin A, Fradin S, de La Sayette V, Eustache F, Chetelat G. Relative effect of APOE epsilon4 on neuroimaging biomarker changes across the lifespan. Neurology. 2016 Oct 18;87(16):1696-1703. doi: 10.1212/WNL.0000000000003234. Epub 2016 Sep 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-A01493-38
Identifier Type: -
Identifier Source: org_study_id